MX2018011283A - Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer. - Google Patents
Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer.Info
- Publication number
- MX2018011283A MX2018011283A MX2018011283A MX2018011283A MX2018011283A MX 2018011283 A MX2018011283 A MX 2018011283A MX 2018011283 A MX2018011283 A MX 2018011283A MX 2018011283 A MX2018011283 A MX 2018011283A MX 2018011283 A MX2018011283 A MX 2018011283A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- salts
- formula
- cinnolin
- treating cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- DODZTSARNRLOKY-UHFFFAOYSA-N cinnolin-4-amine Chemical class C1=CC=C2C(N)=CN=NC2=C1 DODZTSARNRLOKY-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 8
- 150000003839 salts Chemical class 0.000 abstract 8
- XRKYMMUGXMWDAO-UHFFFAOYSA-N 2-(4-morpholinyl)-6-(1-thianthrenyl)-4-pyranone Chemical compound O1C(C=2C=3SC4=CC=CC=C4SC=3C=CC=2)=CC(=O)C=C1N1CCOCC1 XRKYMMUGXMWDAO-UHFFFAOYSA-N 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta memoria descriptiva se refiere en general a compuestos de Fórmula (I): (ver Fórmula) (I) Y sales farmacéuticamente aceptables de los mismos, donde R1, R2 y R3 tienen cualquiera de los significados definidos en el presente documento. La memoria descriptiva también se refiere al uso de dichos compuestos y sales de los mismos para tratar o prevenir una enfermedad mediada por ATM cinasa, incluyendo el cáncer. La memoria descriptiva se refiere además a formas cristalinas de compuestos de Fórmula (I) y sales farmacéuticamente aceptables de los mismos; composiciones farmacéuticas que comprenden dichos compuestos y sales de los mismos; kits que comprenden tales compuestos y sales de los mismos; métodos de fabricación de dichos compuestos y sales de los mismos; intermedios útiles en la fabricación de dichos compuestos y sales de los mismos; y a los métodos para tratar una enfermedad mediada por ATM, incluyendo el cáncer, usando compuestos de Fórmula (I) y sales de los mismos, en solitario o junto con otras terapias.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662310883P | 2016-03-21 | 2016-03-21 | |
| PCT/EP2017/056592 WO2017162605A1 (en) | 2016-03-21 | 2017-03-20 | Cinnolin-4-amine compounds and their use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018011283A true MX2018011283A (es) | 2019-05-27 |
Family
ID=58361025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018011283A MX2018011283A (es) | 2016-03-21 | 2017-03-20 | Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20190099421A1 (es) |
| EP (1) | EP3433251A1 (es) |
| JP (1) | JP2019512512A (es) |
| KR (1) | KR20180127419A (es) |
| CN (1) | CN108884084A (es) |
| AR (1) | AR107937A1 (es) |
| AU (1) | AU2017237394A1 (es) |
| BR (1) | BR112018068347A2 (es) |
| CA (1) | CA3017035A1 (es) |
| CO (1) | CO2018010951A2 (es) |
| DO (1) | DOP2018000197A (es) |
| IL (1) | IL261648A (es) |
| MA (1) | MA43733A (es) |
| MX (1) | MX2018011283A (es) |
| PE (1) | PE20181895A1 (es) |
| SG (1) | SG11201806982PA (es) |
| TW (1) | TW201808939A (es) |
| WO (1) | WO2017162605A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111344293A (zh) * | 2017-09-20 | 2020-06-26 | 阿斯利康(瑞典)有限公司 | 1，3-二氢咪唑并[4，5-c]噌啉-2-酮化合物及其在治疗癌症中的用途 |
| AU2019233596A1 (en) * | 2018-03-14 | 2020-10-08 | Merck Patent Gmbh | Compounds and uses thereof to treat tumors in a subject |
| KR102813324B1 (ko) * | 2018-09-14 | 2025-05-26 | 수저우 잔롱 파마 리미티드 | 모세혈관확장성 운동실조증 돌연변이(ATM) 키나제의 선택적 조절제로서의 1-이소프로필-3-메틸-8-(피리딘-3-일)-1,3-디하이드로-2H-이미다조[4,5-c]신놀린-2-온 및 이의 용도 |
| EP4171651A1 (en) | 2020-06-24 | 2023-05-03 | AstraZeneca UK Limited | Combination of antibody-drug conjugate and atm inhibitor |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| HUP9901155A3 (en) | 1996-02-13 | 2003-04-28 | Astrazeneca Ab | Quinazoline derivatives as vegf inhibitors |
| ATE211134T1 (de) | 1996-03-05 | 2002-01-15 | 4-anilinochinazolin derivate | |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| CL2008000191A1 (es) * | 2007-01-25 | 2008-08-22 | Astrazeneca Ab | Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer. |
| JP2014506878A (ja) | 2011-01-28 | 2014-03-20 | ノバルティス アーゲー | Ｃｄｋ９阻害剤としての置換ビ−ヘテロアリール化合物およびそれらの使用 |
| JP6047556B2 (ja) * | 2011-05-23 | 2016-12-21 | エラン ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | Ｌｒｒｋ２キナーゼ活性の阻害剤 |
| NO2714752T3 (es) * | 2014-05-08 | 2018-04-21 |
-
2017
- 2017-03-20 JP JP2018549311A patent/JP2019512512A/ja active Pending
- 2017-03-20 CA CA3017035A patent/CA3017035A1/en not_active Abandoned
- 2017-03-20 MX MX2018011283A patent/MX2018011283A/es unknown
- 2017-03-20 BR BR112018068347A patent/BR112018068347A2/pt not_active IP Right Cessation
- 2017-03-20 KR KR1020187030086A patent/KR20180127419A/ko not_active Withdrawn
- 2017-03-20 US US16/086,742 patent/US20190099421A1/en not_active Abandoned
- 2017-03-20 AU AU2017237394A patent/AU2017237394A1/en not_active Abandoned
- 2017-03-20 EP EP17712123.3A patent/EP3433251A1/en not_active Withdrawn
- 2017-03-20 PE PE2018001829A patent/PE20181895A1/es not_active Application Discontinuation
- 2017-03-20 MA MA043733A patent/MA43733A/fr unknown
- 2017-03-20 SG SG11201806982PA patent/SG11201806982PA/en unknown
- 2017-03-20 WO PCT/EP2017/056592 patent/WO2017162605A1/en active Application Filing
- 2017-03-20 CN CN201780017874.XA patent/CN108884084A/zh active Pending
- 2017-03-20 TW TW106109172A patent/TW201808939A/zh unknown
- 2017-03-21 AR ARP170100697A patent/AR107937A1/es unknown
-
2018
- 2018-09-06 IL IL261648A patent/IL261648A/en unknown
- 2018-09-18 DO DO2018000197A patent/DOP2018000197A/es unknown
- 2018-10-12 CO CONC2018/0010951A patent/CO2018010951A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018068347A2 (pt) | 2019-01-15 |
| IL261648A (en) | 2018-10-31 |
| MA43733A (fr) | 2018-11-28 |
| TW201808939A (zh) | 2018-03-16 |
| DOP2018000197A (es) | 2018-10-15 |
| KR20180127419A (ko) | 2018-11-28 |
| CA3017035A1 (en) | 2017-09-28 |
| CN108884084A (zh) | 2018-11-23 |
| SG11201806982PA (en) | 2018-09-27 |
| AR107937A1 (es) | 2018-06-28 |
| WO2017162605A1 (en) | 2017-09-28 |
| US20190099421A1 (en) | 2019-04-04 |
| AU2017237394A1 (en) | 2018-11-01 |
| CO2018010951A2 (es) | 2018-10-22 |
| JP2019512512A (ja) | 2019-05-16 |
| EP3433251A1 (en) | 2019-01-30 |
| PE20181895A1 (es) | 2018-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501350A1 (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
| PH12016502168B1 (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| PH12020551315A1 (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| PH12018500958A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| PH12020552148A1 (en) | Purinone compounds and their use in treating cancer | |
| PH12016502394A1 (en) | 1, 3, 4-thiadiazole compounds and their use in treating cancer | |
| PH12018500957A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| PH12018500532A1 (en) | 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer | |
| SA518392101B1 (ar) | ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ | |
| MX378957B (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la ret quinasa | |
| MD20170016A2 (ro) | Compuşi aminopirimidinici ca inhibitori JAK | |
| MX371304B (es) | Dihidropirrolopiridinas inhibidoras del receptor huérfano-gamma. | |
| PH12019502086A1 (en) | Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| MX2018011283A (es) | Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer. | |
| MX2018004879A (es) | Nuevos derivados de piridona y su uso como inhibidores de quinasas. |